References
- Shea T C, Beaven A W, Moore D T, Serody J S, Gabriel D A, Chao N, et al. Sequential high-dose Ifosfamide (I), Carboplatin (C), and Etoposide (E) with Rituximab (R) for relapsed Hodgkin and Large B Cell non-Hodgkin Lymphoma: increased toxicity without improvement in progression-free survival. Leuk Lymphoma 2009; 50: 741–748
- Goldie J H, Coldman A J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727–1733
- Coldman A J, Goldie J H. Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin Oncol 1987; 14(4 Suppl 4)29–33
- Goldie J H, Coldman A J, Gudauskas G A. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982; 66: 439–449
- Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977; 61: 1307–1317
- Gregory S A, Trümper L. Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes. Ann Oncol 2005; 16: 1413–1424
- Moskowitz C H, Bertino J R, Glassman J R, Hedrick E E, Hunte S, Coady-Lyons N, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776–3785
- Kewalramani T, Zelenetz A D, Nimer S D, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684–3688